Cambium Bio Ltd · ASX:CMB
Cambium Bio — Investor Presentation (August 2019)
14 slides from Cambium Bio's investor presentation, Aug 1, 2019
Slide 1: Rights Issue Investor Presentation
Rights Issue Investor Presentation 1 August 2019 Regeneus Ltd (ASX:RGS)
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER Overview: This investor presentation (“Presentation”) has been prepared by Regeneus Ltd (“Regeneus” or “Company”) and is dated 1 August 2019. This Presentation has been prepared in relation to a placement and entitlement offer of new Regeneus ordinary shares (“New Sha
Slide 3: Terms of Offer
Terms of Offer • Partially underwritten 1 for 6 pro rata non-renounceable entitlement offer of new shares in Regeneus at an offer price of $0.08 per New Share • Offer open date 13 August 2019 • Entitlement Offer closes at 5.00pm (Sydney time) on 27 August 2019 3 1 August 2019 Rights Issue Investor P
Slide 4: Terms of Offer
Terms of Offer • Partially underwritten 1 for 6 pro rata non-renounceable entitlement offer of new shares in Regeneus at an offer price of $0.08 per New Share • Offer open date 13 August 2019 • Entitlement Offer closes at 5.00pm (Sydney time) on 27 August 2019 4 1 August 2019 Rights Issue Investor P
Slide 5: Use of Funds
Use of Funds Costs associated with ‘Revised Strategic Focus’ $500k Ongoing working capital to facilitate Progenza Phase 2 development, $3.600K including R&D 5 1 August 2019 Rights Issue Investor Presentation 2019
Slide 6: Value Creation Plan
Value Creation Plan: • Capital Preservation - Focus Pipeline on Commercialization and Platform Development (shots-on-goal) through scientific collaboration • Optimize cost base to create runway to commercialization • Further monetize our assets through BD (regional deals and divestments) • IR strate
Slide 7: Driving Shareholder Value with Consistent News Flow
Driving Shareholder Value with Consistent News Flow 2019 2020 2021 2022 2023 2024 2025 2026 GMP Manufacturing P2 Reg Japan OA Japan License Deal Japan Launch P2 P3 Reg US/EU Launch US/EU OA Partnership for Japan Japan Japan US, Asia and LA Phase 2 Launch Business License Deal Commercial and Research
Slide 8: Prioritize High Value Assets to Commercialization; Platform Development Through Scientific Partnerships
Prioritize High Value Assets to Commercialization; Platform Development Through Scientific Partnerships Sell / Research Focus License Partnership out Human Stem Cell Progenza Animal Health Platform Neuropathic Pain Progenza Sygenus New Cancer Vaccine Knee OA Indication 8 1 August 2019 Rights Issue I
Slide 9: Portfolio - Therapeutic Candidates
Portfolio - Therapeutic Candidates Preclini Phase Phase Approv Program Technology Funding Plan Indication Phase 1 Filing cal 2 3 al Progenza Allogeneic Osteoarthritis of ™ Adipose MSC Focus Knee plus MSC Secretions with Neuropathic Bioactive Collaboration Pain Molecules & Exosomes* Other Collaborati
Slide 10: Patent Portfolio Update
Patent Portfolio Update Key patents granted 100+ Patents or Patent Applications • Patent granted or allowed in US, Europe, Australia, NZ and Japan covering across 14 Patent Families Progenza technology – “allogeneic stem cells and secretions for the treatment of osteoarthritis and other inflammatory
Slide 11: Global Market of Knee Osteoarthritis
Global Market of Knee Osteoarthritis Global Data estimates for Prevalent Knee OA 60 2019 2026 50 • Knee and hip OA rank 13th globally for Prevalence of Knee OA (millions) Years Living with a Disability +56% 40 (2000 → 2016) 30 US Lifetime costs of $140k/person 20 • US Economic costs = $486b (2014) 1
Slide 12: Investment Risks
Investment Risks Japan Deal Completion AGC Exclusive Manufacture contract termination Competition Meeting Phase 2 End Points Risk Factors Liquidity risk 12 1 August 2019 Rights Issue Investor Presentation 2019
Slide 13: Proforma Consolidated Statement of Financial Position
Proforma Consolidated Statement of Financial Position Consolidated Statement of Financial Position 30-Jun-19 Ca pi ta l Proforma The Proforma Consolidated Statement of Financial $'000's Unaudited Ra i s i ng Position (Balance Sheet) is based upon the Current Assets unaudited financial statements as
Slide 14: Contact
Contact Sandra McIntosh Company Secretary and Investor Relations P: +61 2 9499 8010 M: +61 450 253 059 E: sandra.mcintosh@regeneus.com.au 14